Low-energy extracorporeal shock wave therapy is associated with reduced inflammation and fibrosis in an E2-induced rat model of endometriosis and remains effective under menopause-mimicking conditions
article
OA: gold
public-domain-us
AI-generated summary
Low-energy extracorporeal shock wave therapy reduced endometriotic lesion size, inflammation, and fibrosis in a rat model, maintaining efficacy under menopause-mimicking conditions.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
BACKGROUND: Endometriosis is an estrogen-dependent inflammatory disorder marked by ectopic lesions, chronic pelvic inflammation, and frequent recurrence. Extracorporeal shock wave therapy (ESWT) is a non-invasive modality with anti-inflammatory and regenerative potential, but its efficacy under varying estrogen conditions remains unclear.
METHODS: Endometriosis-like lesions were induced in female rats by suturing uterine fragments to the peritoneum, followed by daily 17β-estradiol (E2) or PBS for 28 days. Sprague-Dawley rats were assigned to control, E2, E2 + ESWT (0.1 or 0.25 mJ/mm2), or ovariectomy (OVX) + ESWT groups. ESWT was applied twice weekly for three weeks. Body weight, food intake, lesion morphology, histology, and serum E2 were assessed. Inflammatory and fibrotic markers were analyzed as follows: transforming growth factor beta (TGF-β) and tumor necrosis factor-alpha (TNF-α) were evaluated by both immunohistochemistry (IHC) and quantitative real-time RT-PCR (qRT-PCR), whereas interleukin (IL)-6, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), cyclooxygenase (COX)-2, vascular endothelial growth factor (VEGF), cytokeratin (CK)-18, superoxide dismutase (SOD), inducible nitric oxide synthase (iNOS), and hypoxia-inducible factor-1 alpha (HIF-1α) were assessed by qRT-PCR only.
RESULTS: E2 reduced body weight and food intake and induced cystic peritoneal lesions with upregulated fibrotic and inflammatory markers. ESWT at both energy levels significantly reduced lesion size, cystic formation, the number of endometrial glands (hematoxylin-eosin, H&E staining), fibrosis area ratio (Masson trichrome staining), and expression of fibrosis-, inflammation- oxidative stress-, and hypoxia-related genes and proteins regardless of ovarian status. OVX combined with ESWT produced comparable or slightly enhanced reductions in several markers. ESWT did not alter systemic E2 levels, whereas OVX resulted in reduced serum estrogen levels.
CONCLUSION: Low-energy ESWT attenuated E2-induced endometriotic lesions, accompanied by reductions in proliferation, inflammation, and fibrosis, without altering circulating estrogen levels. These effects were also observed under menopause-mimicking conditions with controlled estrogen exposure. These findings suggest that ESWT may serve as a complementary non-hormonal adjunctive approach and may provide a useful experimental framework for future mechanistic and preclinical studies.
My notes (saved in your browser only)
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (47)
- Advances in the management of endometriosis: an update for clinicians via openalex
- An Update on the Multifaceted Role of NF-kappaB in Endometriosis via openalex
- A Preliminary Investigation of the Roles of Endometrial Cells in Endometriosis Development via In Vitro and In Vivo Analyses via openalex
- Chrysin-loaded PLGA nanoparticles alleviate the implantation of endometriotic lesions via attenuation of peritoneal inflammation and downregulating NF-κB activation-driven expression of angiogenic factors via openalex
- Curcumin Attenuates TNF‐α‐induced Expression of Intercellular Adhesion Molecule‐1, Vascular Cell Adhesion Molecule‐1 and Proinflammatory Cytokines in Human Endometriotic Stromal Cells via openalex
- Decoy receptor 3 promotes cell adhesion and enhances endometriosis development via openalex
- Dienogest in long-term treatment of endometriosis via openalex
- Effects of inhibiting the PI3K/Akt/mTOR signaling pathway on the pain of sciatic endometriosis in a rat model via openalex
- Endometriosis: A Review via openalex
- Endometriosis treatment with shock waves: A novel approach via openalex
- Health-related quality of life burden of women with endometriosis: a literature review via openalex
- Hormonal therapy for endometriosis: from molecular research to bedside via openalex
- Hypoxia-induced interleukin-6 expression in endometriotic stromal cells via openalex
- Linaclotide treatment reduces endometriosis-associated vaginal hyperalgesia and mechanical allodynia through viscerovisceral cross-talk via openalex
- Long term treatment of endometriosis associated pain (EAP) with linzagolix: efficacy and safety after 12 months of treatment via openalex
- Neutrophil recruitment and function in endometriosis patients and a syngeneic murine model via openalex
- Pathogenesis Based Diagnosis and Treatment of Endometriosis via openalex
- Safety of current strategies to manage moderate to severe pain in patients with endometriosis via openalex
- The Abundance and Function of Neutrophils in the Endometriosis Systemic and Pelvic Microenvironment via openalex
- The Role of NF-κB in Endometrial Diseases in Humans and Animals: A Review via openalex
- Transvaginal Low Intensity Shockwave Therapy in Endometriosis (T-LISTE): Protocol for a Randomised pilot trial via openalex
- W4393352854 via openalex
- W4401534543 via openalex
- W4401930056 via openalex
- W4403760700 via openalex
- W4404928336 via openalex
- W4402749531 via openalex
- W1973640443 via openalex
- W1990191217 via openalex
- W2030152719 via openalex
- W2032760014 via openalex
- W2074880336 via openalex
- W2102662649 via openalex
- W2123035031 via openalex
- W2133456153 via openalex
- W2159706091 via openalex
- W2735527928 via openalex
- W2796253106 via openalex
- W2803359464 via openalex
- W2966867472 via openalex
- W2967536257 via openalex
- W3165294846 via openalex
- W3194419458 via openalex
- W3203923355 via openalex
- W4212772998 via openalex
- W4247020019 via openalex
- W4378072163 via openalex
Source provenance
- europepmc
- last seen: 2026-09-27T09:11:36.575535+00:00
- openalex
- last seen: 2026-09-27T06:00:52.009428+00:00
- pubmed
- last seen: 2026-09-26T06:09:20.480971+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine